Skip to main content
Premium Trial:

Request an Annual Quote

System Biosciences Taps Maverix's Platform for Exosome Sequence Analytics Service

Premium

System Biosciences has selected Maverix Biomics' bioinformatics platform to provide the data analysis component of its company's newly launched exosome RNA sequence analytics service, dubbed Exo-NGS.

Under the terms of the arrangement, customers of SBI's service will be able to use Maverix's cloud-based next generation sequence data management, exploration, and visualization platform (BI 11/9/2012) to identify and analyze exosome-associated RNA biomarkers.

The cloud solution includes features such as library sequence quality control metrics, tools for relative RNA abundance and identity analysis, differential expression analysis, and data visualization capabilities such as RNA type charts, expression heatmaps. Users also have access to resources such as the ENCODE data which allows them to explore their data in the context of public datasets.

The financial terms of the agreement are not being disclosed.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.